Read Bill Gates’s 2026 annual letter in full

In his 2026 annual letter Bill Gates warns that 2025 saw a reversal in child mortality—rising from 4.6 million to 4.8 million—and blames reduced support from rich countries after U.S. foreign-aid cuts under the second Trump administration, arguing that a 20% drop in health funding could lead to 12 million additional child deaths by 2045. Gates says he will press governments and communities to restore aid, commit continued philanthropic capital (the foundation has pledged $1.4 billion for climate-resilient farming) and invest billions via Breakthrough Energy into climate tech, while emphasizing AI’s potential to transform healthcare and education and the need for government-led implementation and governance to manage biothreat and job-disruption risks.

Analysis

Market structure: The immediate winners are AI infrastructure and platform providers (MSFT, NVDA, AMZN) and climate/clean‑tech manufacturers that scale with policy and private capital (battery makers, copper/nickel miners). Aid cuts and slower government health spending are a negative for NGOs and contractors that depend on public budgets, compressing revenue for some mid‑cap health services and vaccine distribution firms. Tight GPU supply and differentiated cloud stacks increase pricing power for hyperscalers and premium AI chips; expect sustained capex demand for 12–36 months.

Risk assessment: Tail risks include a major AI safety/biosecurity incident or aggressive regulatory clampdown that could trigger a 25–50% de‑rating in pure‑play AI equities; political backlash from job disruption could accelerate taxation or profit‑sharing proposals over 1–3 years. Near term (weeks/months) watch budget rollouts and hearings; medium/long term (1–5 years) risks are adoption bottlenecks in regulated sectors (healthcare diagnostics, clinical trials) and concentration of philanthropic funding. Hidden dependencies: AI healthcare value realization requires approvals, localized data, and reimbursement policies that can delay revenue by 12–36 months.

Trade implications: Tactical overweight in MSFT (Azure + healthcare AI) and NVDA (chips) for 6–24 month horizons; use LEAPS to capture secular upside while financing with short‑dated call sales. Commodity plays (copper via FCX or COPX) and select climate tech private/public crossover names should be held 12–36 months, adding on pullbacks >10%. Implement tail hedges (buy 3–9 month ATM puts ~5–7% portfolio hedge) to protect against regulatory shocks.

Contrarian angles: Markets underprice the near‑term opportunity from private philanthropic capital and Breakthrough Energy follow‑on funding which can catalyze M&A and non‑dilutive growth in climate tech; that favors small‑cap clean‑tech equity rerating over 12–24 months. Conversely, consensus underestimates regulatory risk to foundation/NGO‑adjacent public contractors—those declines may present acquisition targets. The overreaction risk: a single AI safety scare could create buying windows in fundamentally advantaged incumbents (MSFT, AMZN) rather than long‑term structural damage.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in MSFT via 12–18 month LEAPS (e.g., Jan 2028 calls ~5–10% OTM) to capture Azure + healthcare AI adoption; target +40–60% IRR over 12–24 months, trim if MSFT underperforms Nasdaq by >15% in 90 days or option value falls 50%.
• Allocate 1–2% to NVDA via 9–12 month call LEAPS (or stock if preferred) to play sustained GPU demand; set a tranche add-on on a pullback >15% and buy 10% of the position size in 3‑month ATM puts as a hedge against regulatory/volatility shock.
• Allocate 2% to commodities/clean energy: 1% FCX (Freeport‑McMoRan) + 1% COPX (Global X Copper Miners ETF), time horizon 12–36 months; add 50% more on any >10% pullback and take profits if combined position returns +30–40%.
• Put on a relative value pair: go long MSFT (2%) and short CRM (Salesforce, 2%) for 6–12 months to express infrastructure/AI share gains vs. SaaS margin pressure; take profit if spread widens by 20% and cut if adverse by 10%.